If your angiogram was “fine,” why can a heart attack still happen? In this episode, we explain MINOCA and the AIP clue that can help flag hidden risk—and yes, there’s an AIP calculator included at the end.
🎧 ▶️ Press the play button below to listen in English.
🇨🇳 中文（简体）
如果你的冠状动脉造影显示“没问题”，为什么仍可能发生心肌梗死？本期我们讲清 MINOCA，并介绍能提示隐藏风险的 AIP 指标——文章末尾还附有 AIP 计算器。
请按下方的播放按钮收听。
🇪🇸 Spanish (Latinoamérica)
Si tu angiografía salió “bien”, ¿por qué aún puede ocurrir un infarto? En este episodio explicamos qué es MINOCA y la pista del AIP para detectar riesgo oculto—y al final encontrarás una calculadora de AIP.
Presiona el botón de reproducir para escuchar.
John’s Story: The Angiogram That Didn’t Predict the Heart Attack
John didn’t think he was having a heart problem—at least not at first.
He was in his early 50s, overweight, and he’d been told more than once that his blood pressure was high. Heart disease ran in his family. His father had a heart attack younger than anyone wanted to admit, and John carried that fact around like background noise—always there, but easy to ignore. Like many busy people, he tried not to think about it. He felt “fine” most days.
Then the chest pains started.
At first, it was intermittent—tightness and pressure that came on with exertion and eased with rest. But over a few weeks, it became more frequent, more convincing, and harder to explain away. Given his risk factors—overweight, hypertension, and a strong family history of premature heart disease—his doctor didn’t treat this as anxiety or indigestion. John had the kind of symptoms and risk profile that warranted a closer look.
So his doctor ordered a cardiac stress test—a standard next step when someone has exertional chest discomfort and enough risk factors to make coronary disease a real possibility. John didn’t just “do poorly.” He failed it.
That was enough to escalate quickly. He was referred for coronary angiography, the test most people think of as the “gold standard” for finding blocked coronary arteries. If there was a major narrowing causing his symptoms, the angiogram should show it.
But it didn’t.
The report came back as minimally obstructive coronary artery disease—no high-grade blockage, nothing that looked like a classic “culprit lesion.” John went home relieved. The cardiologist told him he didn’t have a major blockage, and that felt like a free pass. He took the new prescriptions for a while, but nothing else changed—same meals, same schedule, same stress, same habits.
Two months later, he was back in the emergency room with crushing chest pain.
This time it was a heart attack.
And here’s the uncomfortable truth: an angiogram can rule out a big obstruction, but it can’t always rule out the mechanisms that cause heart attacks in people with non-obstructive disease—things like plaque rupture or erosion without severe narrowing, coronary spasm, microvascular dysfunction, spontaneous coronary artery dissection, or a clot that forms and dissolves before anyone sees it.
So the question becomes obvious—and a little frightening:
If John’s angiogram looked reassuring, is there anything that could have warned us that he was still at high risk?
That question is exactly where the study in this article begins.
II. MINOCA: The Heart Attack That Happens Without a Major Blockage
When most people hear the words “heart attack,” they picture a coronary artery that is severely blocked. But there’s a well-described exception: MINOCA, which stands for Myocardial Infarction with Non-Obstructive Coronary Arteries.
What MINOCA means
MINOCA is a true myocardial infarction—with evidence of heart muscle injury and an ischemic clinical picture—but when the patient undergoes coronary angiography, there is no “major” obstructive blockage (typically defined as ≤50% stenosis).
Importantly, MINOCA is not a final diagnosis; it’s a working diagnosis that should trigger a search for the underlying mechanism—because the mechanism determines prevention and treatment.
How common is it?
Niccoli and colleagues make the point very clearly: “MINOCAs represent about 10% of acute coronary syndromes.”
Other large scientific statements and reviews report somewhat different numbers depending on how MINOCA is defined and which populations are studied. For example, the American Heart Association notes a prevalence of around 5–6% of acute MI cases, with reported ranges that can extend higher in some cohorts.
Bottom line: MINOCA is not rare. In a typical hospital or cardiology practice, it shows up often enough that it shouldn’t be dismissed as an oddity—or as “a heart attack that doesn’t count.”
How risky is it?
MINOCA is often misunderstood as a “safer” kind of heart attack. It may be less deadly than MI with obstructive coronary disease in many cohorts, but it is not benign.
- A major ACC review describes MINOCA prognosis as “serious,” citing a ~3.5% 1-year all-cause mortality.
- A global systematic review/meta-analysis reported an unadjusted 12-month all-cause mortality of ~3.4% and a reinfarction rate of ~2.6%.
- An earlier Circulation systematic review reported ~4.7% 12-month all-cause mortality in MINOCA (again, not trivial).
Bottom line: MINOCA is common enough to matter, and dangerous enough that a “non-obstructive” angiogram should not end the conversation—it should start the next layer of risk stratification and prevention.
Why this matters for John
John’s “minimally obstructive” angiogram may have felt reassuring, but MINOCA exists precisely because an angiogram can look non-obstructive and yet a patient can still suffer a real myocardial infarction, through mechanisms that angiography may not fully reveal on its own.
III. The Missing Layer After Angiography: “Non-Obstructive CAD” vs “Normal Coronaries”
After John’s angiogram, the phrase that quietly shaped the rest of his story was: “non-obstructive disease.” To most patients, that sounds almost the same as “normal.” But in MINOCA, those two labels can mean very different risk.
1) What do these two angiogram labels actually mean
On coronary angiography, cardiology teams typically separate patients into two broad buckets:
- Normal coronaries: no visible atherosclerotic narrowing (angiographically “clean” arteries).
- Non-obstructive CAD: there is visible atherosclerosis, but the stenosis is not severe enough to meet the usual “obstructive” threshold—commonly ≤50% stenosis in the setting of MINOCA definitions.
In other words, non-obstructive CAD still means CAD. It’s simply not “tight enough” to be called obstructive.
2) Why angiography can look reassuring—yet still miss danger
A key limitation is that angiography is largely a picture of the lumen (the channel through which blood flows). It’s excellent for finding big narrowings, but it can miss higher-risk biology and structure, including:
- Plaque vulnerability (lipid-rich plaque, inflamed plaque)
- Positive remodeling (the vessel expands outward to “hide” plaque, so the lumen looks relatively preserved)
- Non-lumen mechanisms common in MINOCA (spasm, microvascular dysfunction, plaque erosion/rupture without severe stenosis, SCAD, transient thrombosis)
That “hidden plaque” concept matters because outward (positive) remodeling can preserve the lumen even when plaque burden is substantial—so the angiogram can look “not too bad,” while risk is not.
3) The prognosis gap: “normal” is not the same as “non-obstructive”
This is the clinical punchline: MINOCA patients with non-obstructive CAD tend to do worse than MINOCA patients with completely normal coronaries.
In the AIP–MINOCA study by Abdu et al., more than half of MINOCA patients had non-obstructive CAD (55.3%), while 44.7% had normal coronaries.
During follow-up, the authors emphasize that patients with non-obstructive CAD had a higher risk of MACE than those with completely normal coronaries.
This aligns with external literature showing that, within MINOCA, the presence of non-obstructive atherosclerosis carries a higher risk than truly normal arteries—supporting the idea that “mild” plaque is not automatically “low risk.”
4) Could John’s MINOCA have been prevented?
Guidelines and reviews emphasize that MINOCA isn’t a single diagnosis—it’s a syndrome with multiple possible causes. That’s why experts describe a two-tier approach: first-level tests (including coronary angiography) followed by second-level tests to uncover the real mechanism.
Niccoli and colleagues list these second-level tests as examples: intracoronary imaging, coronary vasomotor testing, cardiac nuclear magnetic resonance, and trans-esophageal or contrast ultrasound. These tests can reveal plaque disruption, spasm, microvascular problems, dissection, or embolic sources—things an angiogram can miss.
But in real life, many patients will never get these tests—because of availability, cost, timing, or insurance barriers. So the question becomes: what can we do that’s cheap, widely available, and still meaningfully improves risk stratification after a “non-obstructive” angiogram?
That’s where the Atherogenic Index of Plasma (AIP) becomes clinically useful. It’s calculated from standard triglycerides and HDL, that is already part of your lipid panel.
In the MINOCA study, we will discuss how AIP helped identify a subgroup with worse outcomes even when angiography didn’t show major obstruction.
IV. What Is Atherogenic Index of Plasma or AIP?
AIP is the base-10 logarithm of the ratio of triglycerides to HDL cholesterol:
AIP = log10(TG / HDL-C)
AIP’s most important detail: units matter
To calculate AIP correctly, TG and HDL-C should be in molar units (mmol/L).
If your lab reports in mg/dL, you either convert first or (easier) use a calculator that handles the conversion for you—exactly why embedding your AIP calculator is so useful.
Why is this ratio biologically meaningful?
AIP compresses two common lipid signals into one:
- Higher triglycerides often reflect a more “remnant-rich” lipid environment.
- Lower HDL-C often travels with insulin resistance and metabolic dysfunction.
AIP was originally proposed as a marker of plasma atherogenicity because it correlates with lipoprotein particle patterns—including a tendency toward smaller, denser LDL particles, which are considered more atherogenic.
In other words, AIP doesn’t just tell you “your TG is high” or “your HDL is low.” It suggests the overall direction of the lipid terrain.
V. The AIP–MINOCA Study: What They Found (and Why John Matters)
Now we get to the study that answers the question behind John’s story:
After an angiogram shows “non-obstructive CAD” (or even normal coronaries), is there a simple, cheap way to identify who is still at higher risk?
1) What the researchers did
In this MINOCA cohort study, published in the European Journal of Internal Medicine, [1] the investigators analyzed 421 patients and separated them into two angiogram categories:
- Normal coronary vessels: 188 patients (44.7%)
- Non-obstructive CAD (<50% stenosis): 233 patients (55.3%)
They then calculated AIP and divided patients into four AIP quartiles (Q1–Q4) with roughly equal group sizes.
A practical detail that matters for real life: discharge medications were similar across AIP groups (lipid-lowering agents, antiplatelets, ACEI/ARB, CCBs, beta blockers).
So differences in outcomes weren’t simply because one group got “better meds” at discharge.
2) Finding #1: Higher AIP was linked to having non-obstructive CAD (even within MINOCA)
Patients in the highest AIP quartile (Q4) showed an increased likelihood of non-obstructive CAD.
Even after adjusting for other factors, AIP remained a significant predictor of non-obstructive CAD, whether treated as a continuous value or by quartile.
In multivariate analysis, AIP as a continuous variable had an OR of 2.172, and being in Q4 had an OR of 1.994 for non-obstructive CAD.
Interpretation: AIP acted like a “metabolic fingerprint” that tracked with underlying atherosclerosis—even when that atherosclerosis was not obstructive.
3) Finding #2: Higher AIP predicted worse prognosis (more MACE)
MACE stands for major adverse cardiovascular events—a combined (“composite”) outcome researchers use to track serious heart- and vessel-related complications over time.
In this study, MACE included cardiac death, nonfatal myocardial infarction, heart failure, stroke, and rehospitalization for angina.
Across follow-up, MACE occurred most often in the highest AIP quartile (Q4):
- Q1: 18.3%
- Q2: 18.4%
- Q3: 20.5%
- Q4: 33.6% (highest)
In survival analysis, Q4 had a significantly higher risk of MACE than the other quartiles (log-rank P = 0.017).
And importantly, even after multivariate adjustment, AIP in the highest quartile remained independently linked to MACE, with an adjusted hazard ratio of around ~2.05.
4) The “worst-case quadrant”: High AIP + non-obstructive CAD
The most clinically useful result is what happened when the authors combined two pieces of information:
- AIP quartile (especially Q4)
- Angiogram category (normal vs non-obstructive CAD)
They found that the highest risk group was Q4 + non-obstructive CAD, which had the greatest MACE risk compared with the other combined groups (log-rank P = 0.027). The correlation of atherogenic …
VI. How does this connect back to John?
John’s angiogram showed minimally obstructive / non-obstructive CAD.
In many real-world settings, that label can accidentally translate into: “Not bad enough to worry.”
This study argues for a different mindset:
If John’s AIP had landed in the highest quartile, the data suggest he would have fit into a group with substantially higher downstream event risk, despite the lack of a big angiographic blockage.
And if John had both non-obstructive CAD and very high AIP, that combination maps onto the study’s highest-risk subgroup—the exact scenario where “reassurance” is most dangerous.
AIP helps answer the question: Could John’s MINOCA have been prevented—or at least anticipated—using a tool that’s inexpensive, widely available, and easy to calculate?
Angiography answered, “Is there a major blockage today?”
AIP helps answer, “Is your lipid/metabolic terrain still pushing you toward an event?”
What changes in prevention strategy when AIP is elevated (especially because discharge meds were similar across groups in the study, yet outcomes still separated)?
VII. How AIP Can Change “What We Do Next”
A “non-obstructive” angiogram can be falsely comforting—especially if the patient hears, “No major blockage.”
The practical value of AIP is that it can push the conversation in the right direction: from reassurance to risk reduction, and from “short-term discharge” to “long-term prevention.”
And to be clear: AIP doesn’t diagnose MINOCA’s mechanism—it helps flag who may still be higher risk.
1) First, don’t stop at the angiogram: MINOCA needs cause-directed thinking
MINOCA is a syndrome with multiple possible mechanisms, and expert statements emphasize that management should be cause-directed when a mechanism is identified (for example, plaque disruption vs vasospasm vs Spontaneous Coronary Artery dissection (SCAD) vs embolic causes).
How AIP changes “what we do next”:
A high AIP is a signal that the person’s lipid/metabolic terrain may be more atherogenic—so clinicians are less likely to stop at “mild disease” and more likely to pursue a structured prevention plan (and, when appropriate, deeper evaluation).
2) AIP as a “risk amplifier” after a non-obstructive angiogram
In the AIP–MINOCA study, the highest AIP quartile had substantially higher event rates, and the highest-risk subgroup was high AIP + non-obstructive CAD.
So if someone has:
- non-obstructive CAD on angiography and
- high AIP,
…it’s a strong argument against “watch and wait.” It’s a cue to treat the situation as high-stakes prevention, not “good news.”
3) What can realistically change in the prevention plan when AIP is high?
A) Lifestyle becomes the main therapy—not a footnote
AIP is built from triglycerides and HDL, so it naturally steers attention toward the behaviors that most strongly move TG/HDL in the right direction—especially in insulin resistance. That means the “real” treatment plan is often:
- Weight and waist reduction (even modest loss can move TG and insulin resistance)
- Exercise with a plan (aerobic + resistance training)
- Lowering refined carbs and added sugars, which often drive TG up
- Alcohol reduction, especially if TG are elevated
- Sleep and stress support, because they influence metabolic risk patterns
This is exactly where John failed: he left the hospital “reassured,” took pills, but didn’t change the exposures that were feeding risk.
B) Follow-up gets tighter (because risk is not “low”)
A practical shift when AIP is high is simply how soon and how seriously you follow up:
- earlier follow-up visit
- repeat lipids (and AIP) after lifestyle/therapy changes
- consider broader cardiometabolic markers (HbA1c, fasting glucose/insulin, apoB/non-HDL-C), depending on clinician preference
C) Medication conversations become more aggressive—but still individualized
Because MINOCA mechanisms vary, medication choices should match the likely cause.
Still, large observational data (like SWEDEHEART) and expert summaries consistently point in one direction: secondary-prevention therapy matters in many MINOCA patients, particularly when an atherosclerotic mechanism is suspected.
Common “prevention backbone” discussions after MINOCA often include:
- Statin therapy and renin–angiotensin system blockers (ACEI/ARB), which have been associated with better outcomes in registry analyses
- Beta-blockers may show a favorable trend in some data, though evidence is less definitive
- Antiplatelet therapy is more nuanced: it may be appropriate when plaque disruption is suspected, but not automatically for every MINOCA mechanism
- If vasospasm is suspected, therapies like calcium channel blockers are often considered in guideline discussions
How AIP changes “what we do next”:
A high AIP doesn’t prescribe a specific drug by itself—but it strengthens the case for:
- not under-treating “mild” angiographic disease
- not delaying aggressive metabolic/lipid risk reduction
- Taking adherence seriously (because outcomes diverge even when discharge meds look similar across groups).
4) A checklist to prevent MINOCA
If your angiogram shows non-obstructive CAD and your AIP is elevated, talk with your clinician about:
- What mechanism is most likely (plaque disruption? spasm? microvascular dysfunction? SCAD? embolic source?)
- Whether you need additional testing (case-by-case)
- A clear prevention plan with targets (BP, LDL/non-HDL/apoB, TG, glucose markers, weight/waist)
- A timeline for repeat labs and follow-up
- A plan to improve medication and lifestyle adherence (because consistency is often the difference-maker)
5) Bring it back to John (one paragraph you can paste)
If John’s AIP had been clearly elevated, it would have been a warning sign that his “non-obstructive” angiogram was not the end of the story. It could have shifted his discharge message from “no major blockage—good news” to “you’re still in a high-risk lane—here’s the prevention plan, here’s what we’re targeting, and here’s when we re-check.”
That’s the core clinical translation: AIP helps decide who needs more urgency after an angiogram that looks reassuring.
VIII. The AIP Calculator
Atherogenic Index (AIP) Calculator
Calculates AIP = log10(Triglycerides ÷ HDL) using mmol/L internally.
Guidepost values (how most papers classify AIP)
You’ll see slightly different cutoffs across studies, but a very common framework is:
- Low risk: AIP < 0.10
- Intermediate risk: AIP 0.10–0.24
- Higher risk: AIP > 0.24
These are guideposts, not destiny. But they’re useful because they give readers a quick way to interpret the number and decide whether this is something to take seriously and discuss with their clinician.
Don’t wait until you develop chest pain, “fail” a stress test, or end up getting an angiogram to take your risk seriously.
AIP is a snapshot of your current lipid/metabolic “terrain,” and if you land in the intermediate- or high-risk range, that’s your cue to start now—before symptoms—by targeting the drivers that most reliably improve triglycerides and HDL
- fat loss when needed
- regular aerobic + resistance exercise,
- cutting added sugars/refined carbs
- limiting alcohol)
- adequate sleep
- alongside a heart-healthy eating pattern
- consistent follow-up with your clinician.
These steps are the foundation of cardiovascular risk reduction across ages, and they’re the same everyday moves that tend to pull AIP down over time.
IX. What this study does not prove (limitations readers should know)
This study is helpful for risk stratification, but it does not prove that AIP causes MINOCA or that lowering AIP will necessarily prevent events. It was a single-center, retrospective observational study with a relatively small sample, focused on a Chinese MINOCA population, so results may not generalize perfectly to every setting. The correlation of atherogenic …
Not every patient underwent the same “second-level” diagnostic workup: CMR wasn’t done in all patients, and intracoronary imaging (which can reveal plaque disruption not seen on angiography) was limited—partly due to real-world feasibility, cost-effectiveness, and insurance constraints—so the investigators could not reliably capture the exact mechanism for each MINOCA case. The correlation of atherogenic …
Finally, the study lacked some potentially informative data, including other lipid markers (like apoB/non-HDL/remnant cholesterol) and details on lipid-lowering therapy during follow-up, which limits how confidently we can interpret treatment effects over time. The correlation of atherogenic …
X. Take-home summary
MINOCA is not a “free pass” diagnosis, and outcomes can be significant—this cohort saw MACE in 22.8% during follow-up.
Within MINOCA, non-obstructive CAD carried a higher risk than completely normal coronaries, indicating that “mild disease” on angiography still matters.
The key clinical message of this study is simple: AIP adds a missing layer after angiography. Higher AIP was independently associated with worse outcomes (a ~2× higher hazard in the highest quartile) and helped identify a higher-risk subgroup, even when no major blockage was present.
Don’t Get Sick!
About Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.
Related:
- Low LDL But Heart Attack Risk: Check AIP Now
- AIP Predicts Heart Attack Risk In Younger Adults
- AIP and Cardiovascular and Atherosclerotic Risk: A Simple TG/HDL Number That Tracks Artery Health
- Atherogenic Index (AIP): Meaning, Clinical Uses and Calculator
- Small Dense LDL: What It Means And How To Improve It
- ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
- LDL Particle Number Explained: A Better Marker Than LDL Cholesterol
- TG/HDL Ratio Explained: What It Means and How to Improve It
- HDL Function Explained: Good vs Bad HDL
- High Triglycerides: Causes, Dangers, And How To Lower
- Metabolic Health Check: Your Metabolic Digest (What It Means + How to Improve It)
- New Science Debunks the Dangers of Saturated Fats on Heart Disease
References:
- Abdu FA, Alifu J, Mohammed AQ, Liu L, Zhang W, Yin G, Lv X, Mohammed AA, Mareai RM, Xu Y, Che W. The correlation of atherogenic index of plasma with non-obstructive CAD and unfavorable prognosis among patients diagnosed with MINOCA. Eur J Intern Med. 2024 Jul;125:111-119. doi: 10.1016/j.ejim.2024.03.024. Epub 2024 Mar 26. PMID: 38538418. https://pubmed.ncbi.nlm.nih.gov/38538418/
- Niccoli, Giampaolo, et al. “Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA).” PMC, 2020, https://pmc.ncbi.nlm.nih.gov/articles/PMC7270909/.
- Cleveland Clinic Journal of Medicine. “Myocardial Infarction with Nonobstructive Coronary Arteries.” CCJM, 1 Dec. 2024, https://www.ccjm.org/content/91/12/743
- Spagnolo, M., et al. “Advances in the Detection and Management of Vulnerable …” Circulation: Cardiovascular Interventions, 2025, https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.125.015529
- AHA (Circulation: Cardiovascular Quality and Outcomes). “Survival in Patients With Suspected Myocardial Infarction With Nonobstructive Coronary Arteries …” 2021, https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.121.007880.
- Stepien, K., et al. “Clinical Characteristics and Long-Term Outcomes of MINOCA …” Frontiers in Cardiovascular Medicine, 2022, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.785246/full
- Tamis-Holland, James E., et al. “Contemporary Diagnosis and Management of Patients with Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association.” Circulation, 2019, https://www.ahajournals.org/doi/10.1161/CIR.0000000000000670
- American College of Cardiology. “MINOCA from A to Z.” ACC.org, 6 Jan. 2022, https://www.acc.org/Latest-in-Cardiology/Articles/2022/01/05/17/41/MINOCA-from-A-to-Z
- Yildiz, Murat, et al. “Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA).” Frontiers in Cardiovascular Medicine, 2022, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1032436/full
Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.
© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.